 This multicenter observer-blind study will determine the safety and reactogenicity of GSK Biologicals investigational HIV vaccine 732461 in two sequentially enrolling cohorts of HIV-infected subjects treated with HAART highly active antiretroviral therapy and HIV infected treatment naïve subjects, respectively. 